Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 12:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 17,825 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Dose level 3 Clear all

Conditions: Tumors, Lymphoma
Interventions: CNF2024; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: Scottsdale, Arizona • New Haven, Connecticut • San Antonio, Texas

Conditions: Neuroendocrine Prostate Cancer (NEPC), Metastatic Prostate Adenocarcinoma, Prostate Cancer
Interventions: Ifinatamab Deruxtecan, Positron Emission Tomography (PET)/Computerized Tomography (CT), Computerized Tomography (CT)/ Magnetic Resonance Imaging (MRI), Bone Scan, Blood Specimen Collection; Drug · Procedure
Lead sponsor: Rahul Aggarwal; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Central Nervous System Tumors
Interventions: 25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®), 50 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®), 100 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®), 150 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®), 150 mg/m2 Lenalidomide (Revlimid®) and 230 mg/m2 Vorinostat (Zolinza®); Drug
Lead sponsor: Johns Hopkins All Children's Hospital; Other
Eligibility: 1 Year to 21 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Neovascular Age-related Macular Degeneration (nAMD)
Interventions: OCU-10-C-110 for Injection; Drug
Lead sponsor: Ocugenix Corporation; Industry
Eligibility: 50 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Carmel, Indiana • Abilene, Texas • Willow Park, Texas

Conditions: Nicotine Dependence, Cigarette Smoking, Alcohol Consumption, Heavy Drinking
Interventions: Varenicline; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Participants
Interventions: AP31969, Carbamazepine, Itraconazole; Drug
Lead sponsor: Acesion Pharma; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Plasmodium Falciparum Infection
Interventions: Chloroquine, PfSPZ (NF54) Challenge, Placebo; Drug · Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Iron Deficiency Anemia, Nondialysis-dependent Chronic Kidney Disease
Interventions: Ferumoxytol, Oral Iron; Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Healthy
Interventions: Ad26.Mos.HIV, MVA-Mosaic, gp140 DP Low-dose, gp140 DP High-dose, Placebo; Biological · Drug
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 393 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2022
U.S. locations: 5
States / cities: Aurora, Colorado • Miami, Florida • Rockville, Maryland + 2 more

Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
Interventions: Busulfan, Gemcitabine, Melphalan, Olaparib, Peripheral Blood Stem Cell Transplantation, Pharmacokinetic Study, Rituximab, Vorinostat; Drug · Procedure · Other + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lupus Nephritis
Interventions: BI 655064 dose 1, BI 655064 dose 2, BI 655064 dose 3, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 9
States / cities: Los Angeles, California • Doral, Florida • Kissimmee, Florida + 6 more

Conditions: Brain Metastases
Interventions: Bendamustine; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Post Operative Pain
Interventions: Morphine; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 3 Years to 18 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Detroit, Michigan • Salt Lake City, Utah

Conditions: Rheumatoid Arthritis
Interventions: AMP-110, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 7
States / cities: Anniston, Alabama • Orlando, Florida • Palm Harbor, Florida + 4 more

Conditions: Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction
Interventions: Tesetaxel; Drug
Lead sponsor: Genta Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: Chicago, Illinois • Philadelphia, Pennsylvania • Houston, Texas

Conditions: Major Depressive Disorder
Interventions: Brexpiprazole, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 70 Years to 85 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Kissimmee, Florida • Miami, Florida • St Louis, Missouri + 1 more

Conditions: Renal Impairment
Interventions: AZD5004; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Miami Lakes, Florida • Orlando, Florida

Conditions: Neonatal Abstinence Syndrome
Interventions: Clonidine, Morphine; Drug
Lead sponsor: Henrietta Bada; Other
Eligibility: 12 Hours to 7 Days
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Healthy
Interventions: Simeprevir 75 mg, Odalasvir 25 mg, Odalasvir 12.5 mg, Odalasvir 75 mg, AL-335 800 mg, Lansoprazole 30 mg, Omeprazole 20 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Multiple Myeloma
Interventions: Arsenic Trioxide, Ascorbic Acid and Bortezomib; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy Volunteers
Interventions: Microgestin®, Levothyroxine, Glyburide, Digoxin, IW-3718; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
Interventions: Ampreloxetine, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 30 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 26
States / cities: Scottsdale, Arizona • Fountain Valley, California • La Jolla, California + 21 more

Conditions: Brain and Central Nervous System Tumors
Interventions: Temozolomide, Radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2022
U.S. locations: 45
States / cities: Phoenix, Arizona • Los Angeles, California • Newark, Delaware + 38 more

Conditions: Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions: Vadadustat, Darbepoetin alfa; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 54
States / cities: Huntsville, Alabama • Mesa, Arizona • Anaheim, California + 45 more

Search by objective public record fields.

Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors

Study of Ifinatamab Deruxtecan in De Novo or Treatment-Emergent Neuroendocrine Prostate Cancer

Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors

Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration

New Approaches to Smoking Cessation in Heavy Drinkers

Drug-drug Interaction Trial of AP31969 and Carbamazepine or Itraconazole

PfSPZ Challenge in Healthy Malaria-Naïve Adults in the United States

A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Nondialysis-Dependent Chronic Kidney Disease

Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis

Study Bendamustine Concurrent Whole Brain Radiation Brain Metastases From Solid Tumors

Morphine PK Subgroup Analysis

Assess Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid Arthritis

Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer

Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder

A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004

Non-Opiate Treatment After Prenatal Opiate Exposure to Prevent Postnatal Injury to the Young Brain

Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC)

Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

Temozolomide and Radiation Therapy in Treating Patients With Gliomas

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)